IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

被引：68

作者：

Leyva, L

Fernández, O

Fedetz, M

Blanco, E

Fernández, VE

Oliver, B

León, A

Pinto-Medel, MJ

Mayorga, C

Guerrero, M

Luque, G

Alcina, A

Matesanz, F

机构：

[1] Hosp Civil, Lab Invest, Malaga 29009, Spain

[2] Hosp Carlos Haya, Serv Neurol, Inst Neurociencias Clin, Malaga 29010, Spain

[3] Hosp Clin San Cecilio, Granada 18012, Spain

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2005年 / 163卷 / 1-2期

关键词：

type I interferon receptor; polymorphism; multiple sclerosis; association; treatment;

D O I：

10.1016/j.jneuroim.2005.02.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFN treatment response in a group of 147 patients and 210 controls undergoing interferon therapy during the last 2 years. Only the 18417 and the 11876 SNPs showed an association with disease susceptibility (p = 0.001 and 0.035, respectively) although no differential genotype distribution were observed between interferon responders and non-responder MS patients. No alteration of the expression level of IFNAR-1 was observed with respect to the -408 genotypes or to interferon treatment response. These data suggest a role for the IFNAR pathway in susceptibility to MS. (C) 2005 Elsevier B.V. All rights reserved.

引用

页码：165 / 171

页数：7

共 50 条

[21] Interferon-beta treatment in patients with childhood-onset and juvenile multiple sclerosis
Totolyan, NA
Skoromets, AA
ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2004, 104 (09): : 23 - 31
[22] Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report
Dalbjerg, Sara Maria
Tsakiri, Anna
Frederiksen, Jette Lautrup
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 8 : 93 - 95
[23] Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response
Graber, Jerome J.
Ford, David
Zhan, Min
Francis, Gordon
Panitch, Hillel
Dhib-Jalbut, Suhayl
JOURNAL OF NEUROIMMUNOLOGY, 2007, 185 (1-2) : 168 - 174
[24] Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal
Khabirov, F. A.
Babicheva, N. N.
Khaibullin, T. I.
Averyanova, L. A.
Granatov, E. V.
Akhmedova, G. M.
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (09) : 113 - 122
[25] Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
Martinez-Rodriguez, J. E.
Lopez-Botet, M.
Munteis, E.
Rio, J.
Roquer, J.
Montalban, X.
Comabella, M.
CLINICAL IMMUNOLOGY, 2011, 141 (03) : 348 - 356
[26] HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis
Comabella, M.
Fernandez-Arquero, M.
Rio, J.
Guinea, A.
Fernandez, M.
Cenit, M. C.
de la Concha, E. G.
Montalban, X.
JOURNAL OF NEUROIMMUNOLOGY, 2009, 210 (1-2) : 116 - 119
[27] Interferon-beta treatment in multiple sclerosis patients decreases the number of monocytes in peripheral blood
Anlar, O
Tombul, T
Ozbek, H
Dilek, L
NEUROSCIENCE RESEARCH COMMUNICATIONS, 2003, 32 (02) : 77 - 81
[28] Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects
Gottberg, K
Gardulf, A
Fredrikson, S
MULTIPLE SCLEROSIS, 2000, 6 (05): : 349 - 354
[29] Coping Strategy and Anxiety Evolution in Multiple Sclerosis Patients Initiating Interferon-Beta Treatment
Moreau, Thibault
Schmidt, Nicolas
Joyeux, Olivier
Bungener, Catherine
Souvignet, Veronique
EUROPEAN NEUROLOGY, 2009, 62 (02) : 79 - 85
[30] Smoking affects the interferon beta treatment response in multiple sclerosis
Petersen, Eva R.
Oturai, Annette B.
Koch-Henriksen, Nils
Magyari, Melinda
Sorensen, Per S.
Sellebjerg, Finn
Sondergaard, Helle B.
NEUROLOGY, 2018, 90 (07) : E593 - E600

← 1 2 3 4 5 →